Why the AMA Wants to Muzzle Your Doctor

There's an editorial on the Wall Street Journal (WSJ.com) titled, "Why the AMA Wants to Muzzle Your Doctor." The editorial is written by Dr. Hal Scherz, a pediatric urological surgeon at Georgia Urology and Children's Healthcare of Atlanta, serves on the faculty of Emory University Medical School and is president and cofounder of Docs4PatientCare.

To read the editorial, visit the WSJ.com and let me know what you think. There are already over 200 comments and I wonder how many of those comments are from Sermo physicians, given that Sermo is currently featuring this story.

Will Roche have the first PPAR agonist?

The Wall Street Journal (WSJ): "Roche Diabetes Drug in Late-Stage Test"

Will Roche be the first with a dual PPAR agonists? Thiazolidinediones (TZDs) like Avandia (rosiglitazone) and Actos (pioglitazone) bind to peroxisome proliferator-activated receptors (PPARs). Several new thiazolidinediones are being investigated as "dual PPAR agonists." One such compound is aleglitazar (made by Roche). My gut tells me that they won't be marketed as TZDs. "Dual PPAR Agonist" sounds better, doesn't it?

A few years ago, AstraZeneca stopped R&D on a similar drug, Galida (tesaglitazar), while Bristol-Myers Squibb (BMS) stopped work on a drug called Pargluva (muraglitazar). TZDs just haven't had much luck, have they? Remember Rezulin (troglitazone)? It was the first TZD and it got pulled from the market because of liver problems.